These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

128 related items for PubMed ID: 26198912

  • 1. Reduction of inflammation and preservation of neurological function by anti-CD52 therapy in murine experimental autoimmune encephalomyelitis.
    Turner MJ, Pang PT, Chretien N, Havari E, LaMorte MJ, Oliver J, Pande N, Masterjohn E, Carter K, Reczek D, Brondyk W, Roberts BL, Kaplan JM, Siders WM.
    J Neuroimmunol; 2015 Aug 15; 285():4-12. PubMed ID: 26198912
    [Abstract] [Full Text] [Related]

  • 2. Alteration of CD39+Foxp3+ CD4 T cell and cytokine levels in EAE/MS following anti-CD52 treatment.
    Pant AB, Wang Y, Mielcarz DW, Kasper EJ, Telesford KM, Mishra M, Haque A, Channon JY, Kasper LH, Begum-Haque S.
    J Neuroimmunol; 2017 Feb 15; 303():22-30. PubMed ID: 28087077
    [Abstract] [Full Text] [Related]

  • 3. Anti-CD52 antibody treatment depletes B cell aggregates in the central nervous system in a mouse model of multiple sclerosis.
    Simon M, Ipek R, Homola GA, Rovituso DM, Schampel A, Kleinschnitz C, Kuerten S.
    J Neuroinflammation; 2018 Aug 11; 15(1):225. PubMed ID: 30098594
    [Abstract] [Full Text] [Related]

  • 4. Laquinimod interferes with migratory capacity of T cells and reduces IL-17 levels, inflammatory demyelination and acute axonal damage in mice with experimental autoimmune encephalomyelitis.
    Wegner C, Stadelmann C, Pförtner R, Raymond E, Feigelson S, Alon R, Timan B, Hayardeny L, Brück W.
    J Neuroimmunol; 2010 Oct 08; 227(1-2):133-43. PubMed ID: 20684995
    [Abstract] [Full Text] [Related]

  • 5. Depletion of CD52-positive cells inhibits the development of central nervous system autoimmune disease, but deletes an immune-tolerance promoting CD8 T-cell population. Implications for secondary autoimmunity of alemtuzumab in multiple sclerosis.
    von Kutzleben S, Pryce G, Giovannoni G, Baker D.
    Immunology; 2017 Apr 08; 150(4):444-455. PubMed ID: 27925187
    [Abstract] [Full Text] [Related]

  • 6. Treatment With CD52 Antibody Protects Neurons in Experimental Autoimmune Encephalomyelitis Mice During the Recovering Phase.
    Hao W, Luo Q, Menger MD, Fassbender K, Liu Y.
    Front Immunol; 2021 Apr 08; 12():792465. PubMed ID: 34975892
    [Abstract] [Full Text] [Related]

  • 7. Inhibiting repulsive guidance molecule-a suppresses secondary progression in mouse models of multiple sclerosis.
    Tanabe S, Fujita Y, Ikuma K, Yamashita T.
    Cell Death Dis; 2018 Oct 17; 9(11):1061. PubMed ID: 30333477
    [Abstract] [Full Text] [Related]

  • 8. Anti-mouse CD52 monoclonal antibody ameliorates iron-deficient anaemia in IL-10 knockout mice.
    Wang H, Dong J, Zuo L, Liu J, Zhu W, Li Y, Gu L, Zhao J, Zhang L, Gong J, Zhang W, Li N, Li J.
    Br J Nutr; 2014 Mar 28; 111(6):987-95. PubMed ID: 24160470
    [Abstract] [Full Text] [Related]

  • 9. Impact of antimouse CD52 monoclonal antibody on graft's γδ intraepithelial lymphocytes after orthotopic small bowel transplantation in mice.
    Shen B, Yu H, Hao X, Qu L, Cai X, Li N.
    Transplantation; 2013 Mar 15; 95(5):663-70. PubMed ID: 23503501
    [Abstract] [Full Text] [Related]

  • 10. Immune status following alemtuzumab treatment in human CD52 transgenic mice.
    Turner MJ, Lamorte MJ, Chretien N, Havari E, Roberts BL, Kaplan JM, Siders WM.
    J Neuroimmunol; 2013 Aug 15; 261(1-2):29-36. PubMed ID: 23759318
    [Abstract] [Full Text] [Related]

  • 11. The therapeutic effect of anti-CD52 treatment in murine experimental autoimmune encephalomyelitis is associated with altered IL-33 and ST2 expression levels.
    Barbour M, Wood R, Hridi SU, Wilson C, McKay G, Bushell TJ, Jiang HR.
    J Neuroimmunol; 2018 May 15; 318():87-96. PubMed ID: 29526407
    [Abstract] [Full Text] [Related]

  • 12. Distinct pathological patterns in relapsing-remitting and chronic models of experimental autoimmune enchephalomyelitis and the neuroprotective effect of glatiramer acetate.
    Aharoni R, Vainshtein A, Stock A, Eilam R, From R, Shinder V, Arnon R.
    J Autoimmun; 2011 Nov 15; 37(3):228-41. PubMed ID: 21752599
    [Abstract] [Full Text] [Related]

  • 13. A novel Raji-Burkitt's lymphoma model for preclinical and mechanistic evaluation of CD52-targeted immunotherapeutic agents.
    Lapalombella R, Zhao X, Triantafillou G, Yu B, Jin Y, Lozanski G, Cheney C, Heerema N, Jarjoura D, Lehman A, Lee LJ, Marcucci G, Lee RJ, Caligiuri MA, Muthusamy N, Byrd JC.
    Clin Cancer Res; 2008 Jan 15; 14(2):569-78. PubMed ID: 18223233
    [Abstract] [Full Text] [Related]

  • 14. In vitro and in vivo evaluation of direct rhenium-188-labeled anti-CD52 monoclonal antibody alemtuzumab for radioimmunotherapy of B-cell chronic lymphocytic leukemia.
    De Decker M, Bacher K, Thierens H, Slegers G, Dierckx RA, De Vos F.
    Nucl Med Biol; 2008 Jul 15; 35(5):599-604. PubMed ID: 18589304
    [Abstract] [Full Text] [Related]

  • 15. Immune cell derived BDNF does not mediate neuroprotection of the murine anti-CD52 antibody in a chronic autoimmune mouse model.
    Demir S, Pitarokoili K, Linker R, Gold R.
    J Neuroimmunol; 2019 Mar 15; 328():78-85. PubMed ID: 30623801
    [Abstract] [Full Text] [Related]

  • 16. Characterisation of a Novel Anti-CD52 Antibody with Improved Efficacy and Reduced Immunogenicity.
    Holgate RG, Weldon R, Jones TD, Baker MP.
    PLoS One; 2015 Mar 15; 10(9):e0138123. PubMed ID: 26372145
    [Abstract] [Full Text] [Related]

  • 17.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 18. B-cell depletion abrogates T cell-mediated demyelination in an antibody-nondependent common marmoset experimental autoimmune encephalomyelitis model.
    Jagessar SA, Heijmans N, Bauer J, Blezer EL, Laman JD, Hellings N, 't Hart BA.
    J Neuropathol Exp Neurol; 2012 Aug 15; 71(8):716-28. PubMed ID: 22805775
    [Abstract] [Full Text] [Related]

  • 19. Antimouse CD52 monoclonal antibody inhibits established spontaneous colitis in IL-10-deficient mice.
    Zhu WM, Li Y, Yu C, Li N, Li JS.
    Inflamm Bowel Dis; 2011 Jul 15; 17(7):E72-3. PubMed ID: 21538714
    [No Abstract] [Full Text] [Related]

  • 20.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 7.